{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-044212","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2025-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.059351+00:00","generated_at":"2026-05-17T04:35:45.460083+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arvinas presents positive Phase 1 data for ARV-102; biomarker modulation in CSF seen","bullets":["ARV-102 well tolerated up to 200 mg single dose and 80 mg daily; no SAEs or discontinuations.","Dose-dependent CSF exposure confirmed in healthy volunteers and Parkinson's patients.","Daily doses ≥20 mg reduced PBMC LRRK2 by >90%; 200 mg dose in patients achieved 97% reduction.","CSF proteomics showed decreases in lysosomal and neuroinflammatory microglial markers after 14 days.","Arvinas plans to report multiple-dose Parkinson's data in 2026 and initiate Phase 1b PSP trial H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-044212","json":"https://secwatch.observer/filing/0001628280-25-044212.json","markdown":"https://secwatch.observer/filing/0001628280-25-044212.md","text":"https://secwatch.observer/filing/0001628280-25-044212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000162828025044212/0001628280-25-044212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000162828025044212/arvn-20251005.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:35:45.460083+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}